Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23488340 | 0.96 | EGFR (0.37) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488768 | 0.95 | HDAC8 (0.38) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488443 | 0.91 | LGALS3 (0.40) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488235 | 0.91 | LGALS3 (0.40) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488576 | 0.91 | LGALS8 (0.42) | LGALS8 | |
| SCHEMBL23488335 | 0.91 | LGALS3 (0.39) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488206 | 0.89 | LGALS3 (0.39) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488505 | 0.89 | LGALS9 (0.35) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL23488251 | 0.89 | CA2 (0.38) | — | |
| SCHEMBL23488209 | 0.89 | EGFR (0.39) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | LGALS3 156/4885LGALS9 106/4885LGALS1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.